Former Alchemia CEO joins Ascend as chairman
Ascend Biopharmaceuticals has appointed former Alchemia (ASX:ACL) chief Dr Peter Smith to be its new chairman.
The company, which is preparing to enter key clinical trials for two immunotherapy cancer treatments, also named chartered accountant Mark Ewing as a non-executive director.
Smith stepped down as CEO and managing director of Alchemia in January.
Before joining Alchemia, he was CEO and managing director of Amrad Corporation - which was acquired by CSL (ASX:CSL) in 2006 - and the founder of cancer immunotherapy biotech Onyvax.
Ewing is a specialist in providing corporate advice to CEOs. He is currently deputy chairman of the holding company for TEAC Australia and chairman of the advisory board for Pro-Ride Racing.
“Dr Smith has demonstrated his outstanding leadership, commercial and management skills over the course of several decades working across the pharmaceutical and biotechnology sectors,” Ascend CEO Clement Leong said.
“Mr Ewing and Dr Smith both have complementary backgrounds, and both add significant depth and expertise to the board.”
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
